Quidel Corporation (QDEL) News

Quidel Corporation (QDEL)

Today's Latest Price: $268.29 USD

0.49 (-0.18%)

Updated Oct 30 4:15pm

Add QDEL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

Filter QDEL News Items

QDEL News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest QDEL News From Around the Web

Below are the latest news stories about Quidel Corp that investors may wish to consider to help them evaluate QDEL as an investment opportunity.

Quidel Receives Emergency Authorization for First Rapid Antigen “ABC Test”: A Combination Diagnostic Assay for Influenza A+B and COVID-19

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its Sofia® 2 Flu + SARS Antigen FIA, a rapid point-of-care test to be used with the Sofia® 2 Fluorescent Immunoassay Analyzer for the rapid, simultaneous qualitative detection

Business Wire | October 2, 2020

Quidel sees a big jump in Q3 revenues

Quidel ([[QDEL]] +5.4%) expects Q3 revenues in the range of $475-$477M, more than 100% jump sequentially, and much higher than $126.5M reported a year ago."Moving forward, we expect even greater success in augmenting our supply chains and production for our COVID-19 diagnostic products, resulting in $800M or more in revenue in our...

Seeking Alpha | October 1, 2020

Quidel Announces Preliminary Revenue for Third Quarter 2020

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenues in the third fiscal quarter of 2020 to be in the range of $475 million to $477 million. "The entire team at Quidel has truly risen to the challenge of the COVID-19 pandemic, producing and shipping millions of tests to those with the greatest need, and further democrati

Business Wire | October 1, 2020

Trichomonas Rapid Testing Market 2020 – Revenue Status & Forecast Report 2025 | Quidel Corporation, Sekisui Diagnostics, Nanjing Liming Bio-Products, Hologic Inc

Trichomonas Rapid Testing Market 2020 Global Industry research report studies latest Trichomonas Rapid Testing industry aspects market size, share, trends, growth, business overview and Trichomonas Rapid Testing industry scenario during the forecast period (2020-2025). Global Trichomonas Rapid Testing Market overview: Trichomonas rapid

OpenPR | September 30, 2020

Big Ten announces partnerships for daily COVID testing that made football possible; here are the details

Biodesix, Inc., will oversee the onsite testing of Quidel Corporation's antigen test.

PennLive | September 30, 2020

Pregnancy Rapid Test Kits Market 2020: Rising Demand Due To Covid-19||Expected Massive Growth By 2027||Key Vendors- Abbott Laboratories, DCC, Procter & Gamble, SPD Swiss Precision Diagnostic, Quidel, bioMerieux.

The "Pregnancy Rapid Test Kits Market" business report contains worldwide analysis and estimation of various market-related factors that are incredibly crucial for better decision making. Competitive analysis has been carried out in this industry analysis report for the major players

OpenPR | September 28, 2020

I Ran A Stock Scan For Earnings Growth And Quidel (NASDAQ:QDEL) Passed With Ease

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks…

Yahoo Finance | September 21, 2020

Quidel Corporation: Looking for Healthcare Bargains

A steep and broad decline in corporate growth might have been expected. It is the shape, timing and magnitude of the recovery that is the critical issue. With so many companies in steep declines with big drops in the frequency of improvement of both sales growth and profit margins there is no evidence. Q2 2020 […] The post Quidel Corporation: Looking for Healthcare Bargains appeared first on ValueWalk .

ValueWalk | September 16, 2020

Pac-12 has 'high degree of confidence' sports will return with new rapid virus testing contract

The Pac-12 is banking on a rapid coronavirus testing platform with Quidel will clear the way for fall sports to begin sooner than 2021.

CNBC | September 4, 2020

Quidel: Bad News Is Sometimes No News At All

Source:TD Ameritrade Business Description Quidel Corporation (QDEL), produces rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, including, among many other tests, tests for COVID-19. Investment Thesis Many potential investments present a single, major question that's likely to determine ultimate investor returns. In the case of Quidel, the...

Risk Research Inc on Seeking Alpha | September 2, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5458 seconds.